medicationPrescription only (US)FDA-approved as Pravachol and generics for hyperlipidemia and cardiovascular risk reductionNot available over the counter in the US; requires a prescription and periodic liver-enzyme monitoring per labeling
PravastatinBenefits, Dosage & Interactions
Also known as: Pravachol
Pravastatin is a medication belonging to the statin class, primarily used to lower high cholesterol levels and reduce the risk of cardiovascular events such as heart attacks and strokes. It is commercially known by its brand name, Pravachol. It is typically taken in the evening.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 2 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials and regulatory approval on file.
Plasma half-life
1.5–2 h
Typical timing
bedtime
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Pravastatin in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Pravastatin entry is written from. Each number matches an inline marker above.
- [1]Comparison of the Efficacy and Safety of Rosuvastatin versus Atorvastatin, Simvastatin, and Pravastatin across Doses (STELLAR Trial)Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. · The American Journal of Cardiology · 2003 · Peer-reviewed · PMID 12860216
- [2]Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind StudyPaoletti R, Fahmy M, Mahla G, Mizan J, Southworth H · Journal of Cardiovascular Risk · 2001 · Peer-reviewed · PMID 11873095
How to track Pravastatin doses
Tracking Pravastatin well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Pravastatin with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is bedtime. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Pravastatin through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 1.5 h, effects and timing shifts show up over days rather than instantly. Review Pravastatin alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Pravastatin dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Pravastatin?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Pravastatin is a medication belonging to the statin class, primarily used to lower high cholesterol levels and reduce the risk of cardiovascular events such as heart attacks and strokes. It is commercially known by its brand name, Pravachol. While it shares the general mechanism of action with other statins, pravastatin distinguishes itself through its hydrophilic (water-soluble) nature, which may influence its tissue distribution and potential for certain side effects compared to lipophilic (fat-soluble) statins. This characteristic can be relevant in specific patient populations.
The development of statins, including pravastatin, marked a significant advancement in the management of dyslipidemia and the prevention of atherosclerotic cardiovascular disease. Pravastatin was approved by the FDA based on extensive clinical trials demonstrating its efficacy and safety profile. It is typically prescribed as part of a comprehensive cardiovascular risk reduction strategy that includes dietary changes, exercise, and other lifestyle modifications. The medication is available in oral tablet form and is taken once daily.
What does the research say about Pravastatin?
Tap a section to expand.
Pravastatin operates primarily through its action as a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This enzyme plays a crucial role in the mevalonate pathway, which is the rate-limiting step in cholesterol biosynthesis within liver cells. By inhibiting HMG-CoA reductase, pravastatin reduces the production of cholesterol in the liver.
The inhibition of hepatic cholesterol synthesis leads to several physiological responses. First, it decreases the intracellular concentration of cholesterol in liver cells. This reduction prompts the liver to upregulate the expression of low-density lipoprotein (LDL) receptors on its cell surfaces. These increased LDL receptors then bind to and internalize LDL particles from the bloodstream, effectively clearing them from circulation. This process results in a significant reduction in plasma LDL-cholesterol levels, often referred to as 'bad cholesterol'.
Beyond its primary effect on LDL-C, pravastatin also contributes to modest reductions in triglyceride levels and slight increases in high-density lipoprotein (HDL) cholesterol levels, sometimes referred to as 'good cholesterol'. These additional effects contribute to its overall cardiovascular protective profile. Its hydrophilic nature restricts its ability to easily cross cell membranes, particularly the blood-brain barrier, which may contribute to a different side effect profile compared to more lipophilic statins, as suggested by PubChem and clinical observations.
Source for this section: Sources for How does Pravastatin work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefits of pravastatin are centered on its ability to improve lipid profiles and reduce cardiovascular risk. These benefits have been extensively documented in large-scale clinical trials and are recognized by major health organizations like the National Institutes of Health (NIH) and the American College of Cardiology (ACC).
* **Reduction in LDL-C (Low-Density Lipoprotein Cholesterol):** Pravastatin effectively lowers high levels of LDL-C, a key factor in the development of atherosclerosis. Clinical studies have consistently shown significant reductions, contributing to the prevention of plaque formation in arteries.
* **Reduced Risk of Major Cardiovascular Events:** For individuals with existing cardiovascular disease or those at high risk, pravastatin reduces the incidence of non-fatal myocardial infarction (heart attack), stroke, and the need for coronary revascularization procedures. This benefit is well-established through trials जैसे the WOSCOPS and PROSPER studies (as referenced by sources like Cochrane and DrugBank).
* **Primary Prevention of Cardiovascular Disease:** In patients with elevated cholesterol but no prior cardiovascular events, pravastatin has been shown to reduce the risk of developing these events, serving as a primary preventative measure. This is particularly relevant for those with multiple risk factors such as hypertension, diabetes, or a family history of heart disease.
* **Modest Effects on Triglycerides and HDL-C:** While less pronounced than its effect on LDL-C, pravastatin can lead to modest decreases in triglycerides and slight increases in HDL-C, further contributing to a favorable lipid profile.
* **Potential for Anti-inflammatory and Pleiotropic Effects:** Research suggests that statins, including pravastatin, may exert benefits beyond lipid modification, such as anti-inflammatory effects and improvement in endothelial function. These pleiotropic effects may contribute to their overall cardiovascular protective actions, as explored in scientific literature (e.g., from NIH sources).
The efficacy and safety of pravastatin are supported by a substantial body of evidence from clinical trials and epidemiological studies, extensively reviewed by organizations مثل MedlinePlus and the FDA. Key studies have established its role in both primary and secondary prevention of cardiovascular disease.
One of the foundational trials for pravastatin was the **West of Scotland Coronary Prevention Study (WOSCOPS)**, a large-scale primary prevention trial that demonstrated a significant reduction in the risk of myocardial infarction and death from coronary heart disease in men with hypercholesterolemia but no prior history of myocardial infarction. This study, published in prominent medical journals, provided strong evidence for statin use in preventing initial cardiovascular events.
For secondary prevention, the **Pravastatin in Secondary Prevention of Ischaemic Heart Disease in the Elderly (PROSPER) trial** investigated the effects of pravastatin in elderly individuals with a history of vascular disease or at high risk for it. The results showed that pravastatin significantly reduced the risk of major vascular events and myocardial infarction in this population. Similarly, trials involving other statins have also reinforced the class effect observed with pravastatin.
Cochrane reviews of statins generally, and pravastatin specifically, have consistently concluded that they are effective in reducing cardiovascular morbidity and mortality across various patient groups. Meta-analyses of multiple trials, as often cited by NIH resources, further consolidate the evidence, indicating consistent reductions in major cardiovascular events, reflecting a robust evidence base for its prescribed use.
Like all medications, pravastatin can cause side effects, although not everyone experiences them. The incidence and severity can vary. Common side effects are generally mild and temporary, while more serious ones are rare but warrant medical attention. Information on side effects is compiled from sources such as Mayo Clinic and the FDA label.
**Common (may affect up to 1 in 10 people):**
* Muscle pain or tenderness (myalgia)
* Headache
* Nausea
* Diarrhea or constipation
* Indigestion or heartburn
* Flu-like symptoms, including joint pain
**Less Common (may affect up to 1 in 100 people) but more serious:**
* **Myopathy/Rhabdomyolysis:** This is a rare but serious muscle condition characterized by significant muscle pain, tenderness, weakness, and dark urine. It can lead to kidney damage. Early symptoms should be reported to a clinician immediately, especially if accompanied by fever or malaise. Blood tests for creatine kinase (CK) levels are typically used to monitor this.
* **Liver problems:** Although rare, pravastatin can cause elevated liver enzymes, sometimes indicating liver damage. Regular monitoring of liver function tests is often recommended. Symptoms might include unusual tiredness, dark urine, and yellowing of the skin or eyes (jaundice).
* **Allergic reactions:** Swelling of the face, lips, tongue, or throat, leading to difficulty breathing or swallowing, accompanied by hives or rash, requires immediate medical attention.
* **Increased blood sugar levels:** Statins, including pravastatin, have been associated with a small increase in blood glucose and a slightly elevated risk of new-onset diabetes, particularly in individuals already at high risk.
* **Memory loss or confusion:** Some individuals have reported cognitive issues, though these are typically mild, reversible, and infrequent.
Patients should discuss any side effects they experience with their healthcare provider. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Several warnings and precautions are associated with the use of pravastatin, which are crucial for patient safety and effective treatment. These are outlined in regulatory documents such as the FDA label and clinical guidance from bodies like the NIH.
* **Liver Impairment:** Pravastatin should be used with caution in individuals with a history of liver disease or significantly elevated liver enzymes. Periodic liver function tests are recommended before and during treatment. The medication is contraindicated in active liver disease or unexplained persistent elevations of serum transaminases.
* **Muscle Problems:** The risk of myopathy and rhabdomyolysis is a significant concern with statins. This risk increases with higher doses, advanced age, renal impairment, and concomitant use of certain other medications. Patients should be advised to report any unexplained muscle pain, tenderness, or weakness immediately. Pre-existing thyroid conditions, especially uncontrolled hypothyroidism, can also increase muscle-related risks.
* **Diabetes Risk:** While the cardiovascular benefits of statins generally outweigh this risk, a small increase in HbA1c and fasting blood glucose levels and a slight increase in the risk of new-onset diabetes have been observed. This should be considered, particularly in patients with pre-existing risk factors for diabetes.
* **Pregnancy and Breastfeeding:** Pravastatin is contraindicated during pregnancy and breastfeeding due to the potential for harm to the fetus or infant. Lipid-lowering drugs are not considered essential during pregnancy. Females of childbearing potential should use effective contraception during treatment.
* **Alcohol Consumption:** Excessive alcohol consumption can increase the risk of liver damage, and therefore, individuals consuming substantial amounts of alcohol should use pravastatin with caution and under close medical supervision.
* **Kidney Impairment:** Dose adjustments may be necessary in individuals with significant renal impairment, as pravastatin is partially excreted by the kidneys. Clinical guidelines, such as those from DrugBank, typically provide specific recommendations.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Pravastatin is contraindicated in certain situations where its use could cause harm or is deemed unsafe. These contraindications are primarily based on the risk of adverse effects and are highlighted in information from sources like the FDA label and DrugBank.
* **Active Liver Disease:** Individuals with active liver disease, including unexplained persistent elevations of serum transaminases (liver enzymes), should not take pravastatin. This is because the medication is metabolized in the liver and can potentially exacerbate liver damage.
* **Pregnancy:** Pravastatin is contraindicated in pregnant women. Cholesterol and cholesterol derivatives are essential for fetal development, and statins may interfere with these processes. Women of childbearing age must use adequate contraception during pravastatin therapy.
* **Breastfeeding:** It is contraindicated in breastfeeding mothers. It is not known whether pravastatin is excreted in human milk, but due to the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued if pravastatin therapy is initiated.
* **Hypersensitivity:** Individuals with a known hypersensitivity to pravastatin or any component of the formulation should not use this medication. Reactions could include severe allergic responses.
These contraindications are critical to consider to ensure patient safety and prevent potentially serious adverse outcomes. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Combining pravastatin with certain other medications or substances can increase the risk of adverse effects, particularly muscle-related problems or alter its effectiveness. Information on drug interactions is typically provided by the FDA label and DrugBank.
* **Fibrates (e.g., Gemfibrozil, Fenofibrate):** Concomitant use with fibrates significantly increases the risk of myopathy and rhabdomyolysis. Pravastatin should generally be avoided with gemfibrozil due to a substantial increase in risk. If used with fenofibrate, close monitoring is essential.
* **Niacin (in lipid-lowering doses $\ge 1$ g/day):** High doses of niacin, when combined with pravastatin, can increase the risk of muscle toxicity. Careful monitoring is required, and doses may need adjustment.
* **Colchicine:** The co-administration of colchicine with pravastatin has been associated with an increased risk of myopathy and rhabdomyolysis. Caution is advised, and patients should be closely monitored for muscle symptoms.
* **Cyclosporine:** Cyclosporine can significantly increase pravastatin exposure, leading to a higher risk of adverse effects, particularly myopathy. Dose reduction of pravastatin and close monitoring for muscle pain or weakness are necessary.
* **Macrolide Antibiotics (e.g., Erythromycin, Clarithromycin):** While less common with pravastatin compared to some other statins, macrolides can potentially increase statin levels and thus raise the risk of myopathy. Use with caution.
* **Strong CYP3A4 Inhibitors:** Unlike many lipophilic statins, pravastatin is not extensively metabolized by the CYP3A4 enzyme system. This makes it less prone to interactions with potent CYP3A4 inhibitors (like azole antifungals, protease inhibitors, diltiazem, verapamil, amiodarone, grapefruit juice) which can significantly increase the exposure of other statins. However, vigilance is still always good practice.
Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to identify and manage potential interactions. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Pravastatin is typically taken once daily, usually in the evening or at bedtime. The rationale for evening administration stems from the fact that cholesterol synthesis naturally increases during the night, and statins are generally most effective when their peak activity aligns with this increased synthesis. However, the exact timing can sometimes be flexible.
The medication can be taken with or without food, as food does not significantly affect its absorption or effectiveness as indicated by the FDA label. Patients should aim to take their dose at approximately the same time each day to maintain consistent blood levels and maximize efficacy. Consistency is key for long-term management of cholesterol levels.
If a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Doubling up on doses is not recommended. Specific dose timing and adjustments should always be made under the guidance of a licensed clinician who can assess individual needs and responses.
Source for this section: Sources for When should you take Pravastatin?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Pravastatin?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
| Berberine | Caution | Compound pairConfidence: theoretical | Berberine inhibits CYP3A4 and P-glycoprotein, raising statin levels and myopathy risk.Source pending | Separate dosing and monitor for muscle pain; consider lower statin dose. |
| CoQ10 (Ubiquinol) | Complementary | Compound pairConfidence: theoretical | Statins block CoQ10 biosynthesis via the mevalonate pathway; supplementing may reduce muscle symptoms.Source pending | Consider 100–200 mg CoQ10 daily while on a statin. |
| Ubiquinol | Complementary | Compound pairConfidence: theoretical | Statins deplete CoQ10; ubiquinol replenishes it.Source pending | Consider 100 mg ubiquinol daily. |
Frequently asked questions about Pravastatin
Pravastatin is primarily used to lower high cholesterol and triglyceride levels, particularly LDL ('bad') cholesterol. It helps reduce the risk of heart attacks, strokes, and other cardiovascular problems in people with high cholesterol or existing heart disease, as outlined by sources like MedlinePlus.
While blood cholesterol levels may begin to decrease within a few weeks of starting pravastatin, the full therapeutic effects on cholesterol and the associated reduction in cardiovascular event risk typically become evident after several months of consistent use. Regular monitoring by a healthcare provider helps track progress.
Yes, pravastatin can be taken with or without food. Its absorption is not significantly affected by meals. However, it's often recommended to take it in the evening or at bedtime because cholesterol production is higher during the night.
Common side effects include muscle pain, headache, nausea, and indigestion. More serious but rare side effects can include severe muscle problems (myopathy/rhabdomyolysis) and liver issues. Any unusual or severe symptoms should be reported to a clinician immediately, as noted by Mayo Clinic information.
No, pravastatin is generally contraindicated during pregnancy and breastfeeding. It can potentially harm the developing fetus or infant, and women of childbearing potential should use effective contraception while on this medication, according to FDA guidance.
Pravastatin is a medication, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Pravastatin is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 1.5 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Pravastatin with no sign-up.
Pravastatin is typically taken in the evening. The reported plasma half-life is about 1.5 hours, which is what drives how often it is redosed. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a medication like Pravastatin with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Pravastatin: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 1.5 hours is why protocols often split Pravastatin across the day rather than using a single dose. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Pravastatin clears quickly (plasma half-life around 1.5 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Pravastatin the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Pravastatin?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial(opens PubMed in a new tab)Lancet · 2002 · PMID 12457784 · https://pubmed.ncbi.nlm.nih.gov/12457784/
- 2.Pravastatin for lowering lipids(opens PubMed in a new tab)Cochrane Database Syst Rev · 2023 · PMID 37721222 · https://pubmed.ncbi.nlm.nih.gov/37721222/
- 3.INOVASIA Study: A Multicenter Randomized Clinical Trial of Pravastatin to Prevent Preeclampsia in High-Risk Patients(opens PubMed in a new tab)Am J Perinatol · 2024 · PMID 35292944 · https://pubmed.ncbi.nlm.nih.gov/35292944/
- 4.Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies(opens PubMed in a new tab)J Reprod Immunol · 2017 · PMID 29028516 · https://pubmed.ncbi.nlm.nih.gov/29028516/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 9931182(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/9931182
Verify at
Publisher search links for Pravastatin. These are places to check the information — they are not citations, so they are not numbered.
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- Clinical practice guidelines (PubMed)(publisher search, opens in a new tab)National Library of Medicine · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Pravastatin?
Plain-text summary, safe to quote verbatim:
Pravastatin is a medication belonging to the statin class, primarily used to lower high cholesterol levels and reduce the risk of cardiovascular events such as heart attacks and strokes. It is commercially known by its brand name, Pravachol. It is typically taken in the evening.
Source: DoseRoutine — https://doseroutine.com/library/pravastatin
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Pravastatin — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/pravastatin
What compounds are similar to Pravastatin?
Others in the medication category or studied for the same goals.